IL231590A0 - Methylation markers diagnostic of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumors or cancer cells - Google Patents
Methylation markers diagnostic of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumors or cancer cellsInfo
- Publication number
- IL231590A0 IL231590A0 IL231590A IL23159014A IL231590A0 IL 231590 A0 IL231590 A0 IL 231590A0 IL 231590 A IL231590 A IL 231590A IL 23159014 A IL23159014 A IL 23159014A IL 231590 A0 IL231590 A0 IL 231590A0
- Authority
- IL
- Israel
- Prior art keywords
- tumours
- epithelial
- response
- kinase inhibitor
- tumour cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 230000011987 methylation Effects 0.000 title 1
- 238000007069 methylation reaction Methods 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542141P | 2011-09-30 | 2011-09-30 | |
| PCT/US2012/057777 WO2013055530A1 (en) | 2011-09-30 | 2012-09-28 | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL231590A0 true IL231590A0 (en) | 2014-05-28 |
Family
ID=47071458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL231590A IL231590A0 (en) | 2011-09-30 | 2014-03-19 | Methylation markers diagnostic of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumors or cancer cells |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130084287A1 (https=) |
| EP (1) | EP2761025A1 (https=) |
| JP (1) | JP2014531213A (https=) |
| KR (1) | KR20140066783A (https=) |
| CN (1) | CN104066851A (https=) |
| AU (1) | AU2012321248A1 (https=) |
| BR (1) | BR112014007569A2 (https=) |
| CA (1) | CA2849120A1 (https=) |
| IL (1) | IL231590A0 (https=) |
| MX (1) | MX2014003698A (https=) |
| RU (1) | RU2014110228A (https=) |
| SG (1) | SG11201400996SA (https=) |
| WO (1) | WO2013055530A1 (https=) |
| ZA (1) | ZA201401968B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140375671A1 (en) * | 2011-11-28 | 2014-12-25 | University Of Chicago | Method, system, software and medium for advanced image-based arrays for analysis and display of biomedical information |
| AU2014274276A1 (en) * | 2013-05-31 | 2015-12-03 | Onconova Therapeutics, Inc. | Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disorders |
| WO2014205374A1 (en) * | 2013-06-20 | 2014-12-24 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing pancreatic cancer |
| CN105980395A (zh) * | 2013-11-04 | 2016-09-28 | 美国陶氏益农公司 | 最优大豆座位 |
| CN107517590B (zh) * | 2014-07-29 | 2021-11-12 | 威马克生物有限公司 | 与表皮生长因子受体-靶制剂有关的感受性预测用新型生物标志物及其用途 |
| JP6709541B2 (ja) * | 2014-10-17 | 2020-06-17 | 国立大学法人東北大学 | 大腸癌に対する薬物療法の感受性を予測する方法 |
| WO2016094839A2 (en) | 2014-12-12 | 2016-06-16 | Exact Sciences Corporation | Compositions and methods for performing methylation detection assays |
| CA3183545C (en) | 2014-12-12 | 2026-01-13 | Exact Sciences Corporation | Compositions and methods for performing methylation detection assays |
| WO2016193151A1 (en) * | 2015-05-29 | 2016-12-08 | Vito Nv | Epigenetic markers for respiratory allergy |
| CN108350485A (zh) | 2015-10-30 | 2018-07-31 | 精密科学发展有限责任公司 | 血浆dna的多重扩增检测测定以及分离和检测 |
| CN109563546B (zh) | 2016-05-05 | 2022-09-09 | 精密科学发展有限责任公司 | 通过分析甲基化dna来检测肺肿瘤 |
| EP3481954A4 (en) * | 2016-07-06 | 2020-04-15 | Youhealth Biotech, Limited | METHYLIZATION MARKERS FOR LUNG CANCER AND USES THEREOF |
| CN110520543A (zh) * | 2017-03-29 | 2019-11-29 | 中美冠科生物技术（太仓）有限公司 | 确定胃癌对西妥昔单抗敏感性的系统和方法 |
| CN107144695B (zh) * | 2017-04-19 | 2019-02-26 | 南昌大学 | Arl13b蛋白在癌症诊断中的应用 |
| US11408887B2 (en) | 2017-05-22 | 2022-08-09 | The National Institute for Biotechnology in the Negev Ltd. | Biomarkers for diagnosis of lung cancer |
| CN118086498A (zh) * | 2018-01-18 | 2024-05-28 | 纽克莱克斯有限公司 | 用于诊断肺癌的方法 |
| WO2019238792A1 (en) * | 2018-06-15 | 2019-12-19 | Unilever Plc | Epigenetic method to assess sun exposure |
| WO2020112869A1 (en) * | 2018-11-27 | 2020-06-04 | Exact Sciences Development Company, Llc | Characterizing methylated dna, rna, and proteins in the detection of lung neoplasia |
| CN111521810B (zh) * | 2019-02-02 | 2024-06-21 | 中国科学院上海药物研究所 | 癌症患者根据脾酪氨酸激酶进行分层 |
| IL265451B (en) | 2019-03-18 | 2020-01-30 | Frumkin Dan | Methods and systems for the detection of methylation changes in DNA samples |
| CN110283910B (zh) * | 2019-06-21 | 2021-04-20 | 浙江大学 | 目标基因dna甲基化作为分子标志物在制备判别结直肠组织癌变进展试剂盒中的应用 |
| CN111304305B (zh) * | 2020-03-30 | 2023-05-30 | 陕西科技大学 | 一种用于检测egfr基因甲基化的试剂盒及方法 |
| CN111676286B (zh) * | 2020-05-29 | 2023-04-14 | 武汉爱基百客生物科技有限公司 | 肺癌血浆游离dna甲基化检测用的多重pcr引物系统、检测方法及应用 |
| CN114354927B (zh) * | 2021-03-18 | 2025-04-22 | 中国人民解放军陆军特色医学中心 | 唾液酸转移酶st3gal4作为egfr-tki耐药标志物的新应用 |
| CN115772565B (zh) * | 2021-09-08 | 2023-09-05 | 广州市基准医疗有限责任公司 | 用于辅助检测肺癌体细胞egfr基因突变的甲基化位点及其应用 |
| CN114525281B (zh) * | 2022-03-14 | 2024-03-12 | 右江民族医学院 | Esrp1启动子报告基因转录活性可视化及在去甲基化抗癌药物筛选中的应用 |
| CN115651984B (zh) * | 2022-10-20 | 2023-04-14 | 山东大学 | 一种生物标志物在评价肿瘤紫杉类化疗耐药性的应用 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| US6033854A (en) | 1991-12-16 | 2000-03-07 | Biotronics Corporation | Quantitative PCR using blocking oligonucleotides |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| WO1995006137A1 (en) | 1993-08-27 | 1995-03-02 | Australian Red Cross Society | Detection of genes |
| AU7964194A (en) | 1993-10-07 | 1995-05-01 | George Washington University Medical Center, The | Method of treating septic shock using thymosin-alpha1 |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| DE59500788D1 (de) | 1994-05-03 | 1997-11-20 | Ciba Geigy Ag | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| CA2214086C (en) | 1995-04-03 | 2008-07-29 | Novartis Ag | Pyrazole derivatives and processes for the preparation thereof |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| DK9500262U4 (da) | 1995-07-07 | 1996-10-07 | Bonus Energy As | Bundramme til vindmøllehus samt vindmølle omfattende samme |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| AU1441497A (en) | 1996-01-23 | 1997-08-20 | Novartis Ag | Pyrrolopyrimidines and processes for their preparation |
| JP3406763B2 (ja) | 1996-01-30 | 2003-05-12 | 東レ・ダウコーニング・シリコーン株式会社 | シリコーンゴム組成物 |
| GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19629652A1 (de) | 1996-03-06 | 1998-01-29 | Thomae Gmbh Dr K | 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO1997034895A1 (de) | 1996-03-15 | 1997-09-25 | Novartis Ag | NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG |
| EA001595B1 (ru) | 1996-04-12 | 2001-06-25 | Варнер-Ламберт Компани | Необратимые ингибиторы тирозинкиназ |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| US5786146A (en) | 1996-06-03 | 1998-07-28 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
| WO1998007726A1 (en) | 1996-08-23 | 1998-02-26 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6251911B1 (en) | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| AU4779897A (en) | 1996-10-02 | 1998-04-24 | Novartis Ag | Fused pyrazole derivatives and processes for their preparation |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| GB9621757D0 (en) | 1996-10-18 | 1996-12-11 | Ciba Geigy Ag | Phenyl-substituted bicyclic heterocyclyl derivatives and their use |
| WO1998033798A2 (en) | 1997-02-05 | 1998-08-06 | Warner Lambert Company | Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation |
| AU8689298A (en) | 1997-08-05 | 1999-03-01 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
| US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
| US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
| US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
| US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
| US6331393B1 (en) | 1999-05-14 | 2001-12-18 | University Of Southern California | Process for high-throughput DNA methylation analysis |
| CZ20014083A3 (cs) | 1999-05-14 | 2002-08-14 | Imclone Systems Incorporated | Léčivo pro indikaci růstu refrakterních nádorů |
| US6180349B1 (en) | 1999-05-18 | 2001-01-30 | The Regents Of The University Of California | Quantitative PCR method to enumerate DNA copy number |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
| US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
| DE10130800B4 (de) | 2001-06-22 | 2005-06-23 | Epigenomics Ag | Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität |
| AU2003251597A1 (en) | 2002-06-19 | 2004-01-06 | Abgenix, Inc. | Method for predicting response to epidermal growth factor receptor-directed therapy |
| CA2489360C (en) | 2002-06-26 | 2013-01-29 | Cold Spring Harbor Laboratory | Methods and compositions for determining methylation profiles |
| WO2004046386A1 (en) | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
| CA2512536A1 (en) | 2003-01-08 | 2004-07-29 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| AU2004211955B2 (en) | 2003-02-06 | 2009-05-14 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
| JP4453297B2 (ja) | 2003-05-27 | 2010-04-21 | トヨタ自動車株式会社 | 車両用遊星歯車式多段変速機 |
| AU2004248140A1 (en) | 2003-05-30 | 2004-12-23 | Cedars-Sinai Medical Center | Gene expression markers for response to EGFR inhibitor drugs |
| EP1664716A4 (en) | 2003-08-15 | 2008-08-13 | Smithkline Beecham Corp | CANCER BIOMARKERS |
| CA2601157A1 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| TWI487712B (zh) | 2008-09-03 | 2015-06-11 | 建南德克公司 | 多重特異性抗體 |
| WO2010099138A2 (en) * | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010099363A1 (en) * | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
| EP2419177A1 (en) * | 2009-04-17 | 2012-02-22 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| US20140030255A1 (en) * | 2010-11-03 | 2014-01-30 | Merck Sharp & Dohme Corp. | Methods of predicting cancer cell response to therapeutic agents |
-
2012
- 2012-09-28 EP EP12775890.2A patent/EP2761025A1/en not_active Ceased
- 2012-09-28 KR KR1020147011145A patent/KR20140066783A/ko not_active Ceased
- 2012-09-28 MX MX2014003698A patent/MX2014003698A/es unknown
- 2012-09-28 AU AU2012321248A patent/AU2012321248A1/en not_active Abandoned
- 2012-09-28 SG SG11201400996SA patent/SG11201400996SA/en unknown
- 2012-09-28 JP JP2014533357A patent/JP2014531213A/ja active Pending
- 2012-09-28 BR BR112014007569A patent/BR112014007569A2/pt not_active IP Right Cessation
- 2012-09-28 CN CN201280058401.1A patent/CN104066851A/zh active Pending
- 2012-09-28 US US13/630,363 patent/US20130084287A1/en not_active Abandoned
- 2012-09-28 RU RU2014110228/10A patent/RU2014110228A/ru not_active Application Discontinuation
- 2012-09-28 CA CA2849120A patent/CA2849120A1/en not_active Abandoned
- 2012-09-28 WO PCT/US2012/057777 patent/WO2013055530A1/en not_active Ceased
-
2014
- 2014-03-18 ZA ZA2014/01968A patent/ZA201401968B/en unknown
- 2014-03-19 IL IL231590A patent/IL231590A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2849120A1 (en) | 2013-04-18 |
| AU2012321248A1 (en) | 2014-04-24 |
| CN104066851A (zh) | 2014-09-24 |
| BR112014007569A2 (pt) | 2017-04-18 |
| SG11201400996SA (en) | 2014-04-28 |
| MX2014003698A (es) | 2014-07-28 |
| EP2761025A1 (en) | 2014-08-06 |
| KR20140066783A (ko) | 2014-06-02 |
| JP2014531213A (ja) | 2014-11-27 |
| ZA201401968B (en) | 2018-05-30 |
| US20130084287A1 (en) | 2013-04-04 |
| WO2013055530A1 (en) | 2013-04-18 |
| RU2014110228A (ru) | 2015-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL231590A0 (en) | Methylation markers diagnostic of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumors or cancer cells | |
| ZA201405140B (en) | Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors | |
| PL3111950T3 (pl) | Sposoby i kompozycje dotyczące antagonizmu receptora glukokortykoidów i nowotworu prostaty | |
| SI2556071T1 (sl) | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka | |
| ZA201204793B (en) | Substituted naphthyridines and their use as syk kinase inhibitors | |
| GB201100180D0 (en) | Tumour cell and tissue culture | |
| EP2555801A4 (en) | SELECTION AND USE OF HOST CELLS FOR THE MANUFACTURE OF GLYCOPROTEINS | |
| ZA201404958B (en) | Mammalian fetal pulmonary cells and therapeutic use of same | |
| ZA201406726B (en) | Methods and composition related to brown adipose-like cells | |
| GB201200458D0 (en) | Methods of preparing cells and compositions | |
| EP2861767A4 (en) | PREDICTIVE MARKERS FOR CANCER AND METAL CHANGE SYNDROME | |
| PT2910567T (pt) | Mutante da quinase iii do ácido asparagínico, células hospedeiras e sua utilização | |
| SG11201502497RA (en) | Sebocyte cell culturing and methods of use | |
| ZA201503105B (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| IL232466A (en) | Preparations and Methods for Prostate Cancer Analysis | |
| IL245123A0 (en) | Short interfering RNA and its use in methods and preparations for preventing the expression of the orai1 gene | |
| IL237435A0 (en) | Methods for producing cells with a phenotype of primary human hepatocytes and composites | |
| ZA201400892B (en) | Detection of prame gene expression in cancer | |
| AU2016202399A1 (en) | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to EGFR kinase inhibitor in tumours or tumour cells | |
| EP2841556A4 (en) | COMPOSITIONS AND METHOD FOR MODULATING THE SENSITIVITY OF CELLS AGAINST AHAS INHIBITORS | |
| PL2631363T3 (pl) | Konstrukcja drogi i zastosowanie płyty izolacyjnej w konstrukcji drogi | |
| GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201112637D0 (en) | The process of nanostenting and nanomeshing cancer cells | |
| HK1228451A1 (en) | Sirna and their use in methods and compositions for inhibiting the expression of the pdk1 gene |